Monitor progress on Anaphylm resubmission and FDA feedback from the Type A meeting. The stock may react positively if the path to approval is clarified and accelerated review is granted. Watch for execution on cost control in 2026, as EBITDA loss guidance shows improvement despite continued investment. The $5M equity line is non-dilutive for now but could pressure shares if drawn down in a weak market.
Price Chart
Executive Summary
Aquestive Therapeutics reported mixed Q4 and full-year 2025 results, with 10% quarterly revenue growth to $13.0M but a 3% annual decline to $44.5M. The company received a Complete Response Letter (CRL) from the FDA for its Anaphylm NDA due to human factors and PK study deficiencies, delaying approval but not citing clinical or manufacturing issues. It plans resubmission in Q3 2026. Despite higher commercial spending, non-GAAP EBITDA loss widened to $49.7M for the year. The company extended its RTW agreement and secured a $5M committed equity line, guiding to $70M in cash by end-2026.
Key Financial Metrics
Key Facts
- FDA issued a CRL for Anaphylm NDA on January 30, 2026, citing human factors validation and a required PK study; no CMC or clinical deficiencies noted.
- Plans to resubmit Anaphylm NDA in Q3 2026 after completing required studies; Type A meeting with FDA expected within 30 days.
- Q4 2025 revenue increased 10% YoY to $13.0M, driven by manufacturing and supply growth, but full-year 2025 revenue declined 3% to $44.5M.
- Full-year non-GAAP adjusted EBITDA loss widened to $49.7M in 2025 from $23.0M in 2024, primarily due to higher SG&A expenses including $14.3M in legal costs.
- Company entered into $5M committed equity line with RTW-affiliated funds and extended revenue-sharing agreement to June 30, 2027.
- Guides to end FY2026 with $70M in cash; 2026 revenue guidance of $46M–$50M and non-GAAP EBITDA loss of $30M–$35M.
- Cash and equivalents were $121.2M as of December 31, 2025.
Financial Impact
Revenue growth in Q4 but full-year decline; EBITDA loss more than doubled year-over-year. Anaphylm delay pushes potential approval into 2027, impacting near-term revenue potential. $5M equity commitment provides modest runway.
Risk Factors
- FDA may require additional studies or raise new issues during the Anaphylm resubmission review, further delaying approval.
- Cash burn remains high; even with $121.2M on hand, the company may need to raise additional capital before Anaphylm generates revenue.
- Suboxone revenue erosion may accelerate, and new collaborations may not fully offset the decline.
- Equity drawdown from RTW could be dilutive if executed at low share prices.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249714 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 8-K | $4.06 $4.13 | ▲ +1.72% | ▲ +2.74% | $3.97 (−2.22%) |
Oct 15, 2026 11d ago | Press Release | $4.06 $4.13 | ▲ +1.72% | ▲ +2.74% | $3.97 (−2.22%) |
Oct 14, 2026 12d ago | 8-K | $4.61 $4.08 | ▼ −11.50% | ▼ −11.95% | $3.97 (−13.88%) |
Oct 7, 2026 19d ago | SC 13G | $4.62 $4.61 | ▼ −0.22% | ▲ +0.76% | $3.97 (−14.07%) |
Oct 7, 2026 19d ago | SC 13G/A | $4.62 $4.61 | ▲ +0.22% | ▼ −0.76% | $3.97 (+14.07%) |
Sep 29, 2026 27d ago | 8-K | $4.67 $4.61 | ▼ −1.28% | ▼ −3.23% | $3.97 (−14.99%) |
Sep 25, 2026 4w ago | 8-K | $4.68 $4.55 | ▼ −2.78% | ▼ −2.56% | $3.97 (−15.17%) |
Sep 17, 2026 5w ago | 8-K | $4.66 $4.82 | ▲ +3.43% | ▲ +2.83% | $3.97 (−14.81%) |
Sep 16, 2026 5w ago | Insider Cluster | $4.82 $4.70 | ▼ −2.49% | ▼ −5.05% | $3.97 (−17.63%) |
Aug 15, 2026 10w ago | Institutional Cluster | $4.29 $4.80 | ▲ +11.89% | ▲ +13.08% | $3.97 (−7.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers